Two-drug combo for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral drugs (Utidelone and Fruquintinib) for ovarian cancer that has stopped responding to platinum chemotherapy. It may offer a new option when standard treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy (resistant).
- You are between 18 and 70 years old.
- You have at least one tumor that can be measured on scans.
- You have had 3 or fewer previous cancer treatments (not counting first chemo after surgery).
- You are in good enough health to be up and around (ECOG 0 or 1) and your organs are working well.
- You must not have certain cancer types (like clear cell, mucinous, or low-grade tumors) or certain prior treatments (like other anti-angiogenic drugs except Avastin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (etoposide capsules, bevacizumab, and an immunotherapy pair) for ovarian cancer that no longer responds to standard platinum chemotherapy. It aims to find a new treatment option for women with resistant or refractory disease.
This trial tests an oral chemotherapy called Utidelone for people with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. It aims to see if this drug can help when standard options have failed or are not tolerated.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial tests a combination of paclitaxel polymeric micelles and fruquintinib capsules as a second-line treatment for patients with advanced gastric cancer whose first-line therapy with oxaliplatin and fluorouracil has stopped working. The goal is to see if this new drug combination can shrink tumors and how safe it is.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.